About Us
OUR COMPANY
Xenolis Pte Ltd is a life sciences company that specializes in the discovery and development of XenoAptamers for use in life sciences application and research. XenoAptamers are advanced aptamers that contain proprietary unnatural bases and have unique properties and configurations. This allows us to produce aptamers with high affinity and specificity to their targets, making them ideal for broad applications across life sciences.
Xenolis’ proprietary ExSELEX™ platform is a transformative and agnostic technology that impacts multiple sectors of the life science industry via genetic alphabet expansion. This platform extends its utility from research and discovery, translational research and biopharmaceutical development, and clinical applications.
Our team of core scientists, led by Chief Scientific Officer Prof Ichiro Hirao and Research Director Dr Michiko Kimoto, brings over 26 years of experience in aptamer technology. They have contributed significantly to the field with numerous publications in prestigious journals (see publications and are actively collaborating with leading companies and research institutes to develop novel applications.
In 2009, Xenolis’ co-founders, Prof Ichiro Hirao and Dr Michiko Kimoto created two new genetic letters – Ds and Px – which form an artificial base pair that functions as a third DNA base pair.
Dr Hirao said “The inspiration for the design of our new DNA base pair came from jigsaw puzzles- where complementary shapes fit together to form the specific pair.
As of 2023, Xenolis has expanded its technological horizon with patent applications for the new genetic alphabets Bs and Ys, and an enhanced ExSELEX platform utilizing a 6-letter library. This advancement builds on our existing 5-letter library, underlining our commitment to developing superior XenoAptamers tailored to meet the diverse needs of our clients.
OUR VISION
Management
Chua Chee Min
Chief Executive Officer
Co-founder
Michiko Kimoto, Ph.D.
Chief Operating Officer
Co-founder
Scientific Advisors
